# ADR-010: Controlled Continuous Improvement vs Autonomous Self-Modification

## Status
Accepted

## Context
There is a widespread conceptual myth that AI agents should "autonomously learn and modify their own code in production." In enterprise pharmaceutical systems, allowing an LLM to rewrite its own code, reconfigure database connections, or deploy unreviewed prompts is dangerous, non-compliant, and introduces unpredictable breaking changes.

## Decision
We enforce a **Controlled Continuous Improvement Lifecycle** with human-in-the-loop review:
1. Capture execution traces and human reviewer feedback (`FeedbackRecord`).
2. Aggregate recurring failure patterns via `FailureAnalyzer` into standardized categories (`routing_misclassification`, `data_inconsistency`, etc.).
3. Generate structured `ImprovementProposal` records detailing proposed prompt or routing updates.
4. Require explicit human review (`approved` or `rejected`).
5. Require passing the evaluation regression suite prior to release.
6. Absolutely forbid autonomous self-modification or unreviewed prompt deployment.

## Alternatives Considered
1. **Autonomous production prompt rewriting**:
   - *Rejected*: Violates enterprise governance; susceptible to prompt injection attacks and unpredictable regressions.
2. **Automatic fine-tuning from raw chat logs**:
   - *Rejected*: Chat queries contain unverified questions and potential bad actor inputs; fine-tuning without human curation corrupts model weights.

## Consequences & Trade-offs
- **Positive**:
  - Predictable, audited, and safe evolution of agent capabilities.
  - Transparent UI review queue for enterprise developers and stakeholders.
- **Negative / Trade-offs**:
  - Requires human reviewer oversight rather than instantaneous "magic" adaptation.
